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LETTERS TO THE EDITOR
Thrombolysis, the Risk of Rupture and
Other Risks
If results of a retrospective study contradict results of randomized
trials, methodology must be scrutinized. Without randomization there
are often many alternative explanations of observations.
In an analysis of .350,000 patients participating in the United
States National Registry of Myocardial Infarction, Becker et al. (1)
showed that thrombolytic agents, previous myocardial infarction and
intravenous beta-adrenergic blocking agents are independently associ-
ated with cardiac rupture. These findings raise several issues of study
design and interpretation.
Electromechanical dissociation and rupture were the cause of
death in 7.3% of patients in this study. Similar, extremely low rates
were also reported in articles published between 1938 and 1968. Due
to a dramatic decrease in deaths due to arrythmias and deaths due to
pump failure, free wall rupture is now the cause of death in .20% of
patients (2,3). In discordance to the randomized International Study of
Infart Survival (ISIS)-I trial (4), which clearly showed that early
intravenous beta-blockade reduces the incidence of early rupture in
patients with acute myocardial infarction, Becker et al. found that
patients treated with intravenous beta-blockers had a higher incidence
of rupture. Hearts with previous infarction seem to be more resistant
to rupture according to a host of publications by pathologists (5), but
the contrary was found in the report under discussion. The risk of
electromechanical dissociation/rupture was doubled by thrombolysis in
the study by Becker et al. but was not increased in patients treated with
thrombolysis in randomized trials and meta-analyses of randomized
trials (6,7).
The obviously most important pitfalls in this study are the rather
arbitrary criteria used in the definition of causes of death. The cause of
death was based on clinical suspicion rather than on autopsy findings.
However, in patients with acute myocardial infarction, the cause of
death is always uncertain unless autopsy is performed. Subacute
ruptures making up 30% to 45% of all rupture cases may imitate other
causes of death, such as infarct extension, cardiogenic shock or death
due to arrythmias. Autopsy rate, an important variable in this context,
is not mentioned in the report but seems to be very low. In contrast, all
patients with electromechanical dissociation were included in statisti-
cal analysis and as a result were included in conclusions on heart
rupture; but electromechanical dissociation is not always a conse-
quence of rupture, and global ischemia or large infarcts are other
important causes in patients with acute myocardial infarction. The
confounding effect of these incorrect classifications may be enormous.
Therapies, such as thrombolysis, intravenous beta-blocker treat-
ment, or diagnostic modalities, such as autopsies, are not distributed in
a random manner but are limited to strictly defined and totally
different subgroups with unequal risks of rupture and unequal risks of
missing a diagnosis of rupture. Late admission after onset of symptoms
is the most frequent contraindication to thrombolysis, so that the
clustering of ruptures within the first 24 h in the thrombolysis group
may be caused by unequal observation periods. The description of the
survival analysis is not very precise in this respect.
Concerns about the risk of thrombolysis in the elderly are prevalent
among doctors in many countries, leading to shortfalls. In a recent
report (8) on the use of thrombolysis in 11 European countries, the
treatment odds ratio was only 0.24 among patients 75 to 84 years old
who were apparently suitable for thrombolysis. Because reports about
the risks of thrombolysis may have a disproportionate effect on clinical
practice, the risk of drawing conclusions from imprecise data should
also be kept in mind.
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Reply
Pollak raises several interesting questions concerning cardiac rupture.
We appreciate his insightful comments and acknowledge his prior
contribution to the field.
Cardiac rupture is a well recognized and feared complication of
acute myocardial infarction (MI). Despite descriptions dating back to
the mid-17th century (1), questions regarding its pathogenesis remain
unanswered.
The reperfusion era has raised additional questions for the medical
community to ponder. Is rupture the same as it was in the pre-
reperfusion era? What is the impact of reperfusion in general and
thrombolysis in particular? What are the contributions attributable to
thrombin inhibition or the intensity of anticoagulation? Most impor-
tant, can rupture be prevented?
In our composite view derived from the U.S. National Registry of
Myocardial Infarction (NRMI) data base (2), rupture among patients
receiving thrombolytic therapy occurred infrequently (0.7%). Consis-
tent with the findings of randomized studies conducted in the reper-
fusion era, including the Thombolysis in Myocardial Infarction Phase
II (TIMI-II) (3) and Global Utilization of Streptokinase and TPA for
Occluded Arteries (4) studies, rupture accounted for nearly 15% of
in-hospital deaths. The use of clinical criteria, including electrome-
chanical dissociation to diagnose rupture represents a precedent set by
previous investigators (5) who meticulously correlated clinical infor-
mation and pathologic observations (6,7). We potentially underesti-
mated the overall occurrence of rupture by relying on clinical criteria
and focusing predominantly on in-hospital cardiac events. As Pollak
points out, there may be a statistical “shift” toward early rupture as
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deaths due to pump failure and arrhythmias are lessened by successful
reperfusion. It is also conceivable that late ruptures are prevented by
myocardial salvage, once again creating the impression that reperfu-
sion increases the risk of rupture when early mortality is the end point.
We found that despite an “acceleration” of rupture events, mortality
was lower in thrombolytic-treated patients, mitigating against an “early
hazard.”
In the pre-reperfusion era, intravenous beta-blocker administration
(5) and previous MI were thought to protect against rupture. We were
somewhat surprised to find the opposite and cannot offer an explana-
tion at this time. However, as scientific investigators we acknowledge
that reperfusion, thrombolytic therapy and antithrombotic strategies
may create a unique pathologic environment quite different from that
in the pre-reperfusion era (8).
In the GISSI study (9), patients .70 years old had an autopsy-
determined rupture rate of 86%. Our findings are unlikely to decrease
thrombolytic therapy use. Indeed, clinicians are aware that elderly
patients experience an alarmingly high in-hospital mortality rate and,
as a result, stand to benefit greatly from aggressive treatment. Potential
risks and benefits must always be weighed carefully.
The NRMI is the largest observational data base (of MI) in the
United States and currently includes information on .500,000 pa-
tients. Like other registries it is not a substitute for basic investigation
nor can it solve mechanistic questions. The NRMI does serve a vital
role in tracking health care trends and outcomes as well as in
identifying areas in medicine that require more in-depth study.
RICHARD C. BECKER, MD
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Qualitative or Quantitative Assessment of
Spontaneous Echo Contrast?
We note with interest the study by Klein et al. (1) in a recent issue of
the Journal in which a new method of assessing the intensity of left
atrial spontaneous echo contrast (SEC) using integrated backscatter
was compared with a qualitative grading method. We agree with the
authors that the severity of SEC is likely to be an important variable in
stratification of thromboembolic risk, particularly in patients with
nonvalvular atrial fibrillation. Several methods of classifying the sever-
ity of SEC on the basis of factors such as its intensity, distribution
within the left atrium and the gain settings at which it is detected have
been reported previously (2–4). We are concerned by the premise of
Klein et al. that qualitative grading is neither objective nor reproduc-
ible, with the implication that quantitative grading of SEC is required.
Klein et al. claim that interobserver variability is a major limitation
of existing qualitative grading methods. The main evidence cited in
support of this argument is a study by Kronik et al. (5), in which SEC
grading was performed in 88 patients by two independent observers
from two separate laboratories. Kronik et al. found that there was
“good” agreement between the observers (kappa value 0.65) in the
grades allocated. In the study by Klein et al., SEC grades were
determined by consensus of two observers from the same laboratory.
The number of cases in which a discrepancy occurred was not included
in their report. We devised a method of classifying SEC into five grades
that we have used for .7 years in our laboratory. The variability of
SEC grading by two experienced observers using this method (6%) (4)
is comparable to the interobserver variability reported by Klein et al.
for integrated backscatter measurements (4%). In their study, Klein et
al. found a strong, positive correlation between SEC grade and the
integrated backscatter intensities (r 5 0.89, p , 0.001). In a recent
report (6), we demonstrated that qualitative grades correlated highly
with quantitative assessment of SEC using videodensitometric analysis
(r 5 0.85, p , 0.001).
Klein et al. propose a multicenter trial to establish the prognostic
significance of left atrial integrated backscatter measurements. Several
factors need to be considered in designing such a trial: 1) The results
are likely to be confounded by the effects of anticoagulant therapy.
Given the relation between left atrial SEC and left atrial thrombus
(2–4), it would be unethical to withhold or randomize anticoagulant
treatment, particularly in patients with higher grades of SEC. A high
prevalence of anticoagulation in patients with severe SEC would be
expected to mitigate against the demonstration of a positive
relation between SEC grade and thromboembolic events. 2) Al-
though Klein et al. estimate a sample size of 350 patients, we suspect
that a considerably larger number of patients may be required to
achieve statistically significant differences between groups in an anti-
coagulated population. 3) The cost of recruiting patients and providing
integrated backscatter software to a large number of centers needs to
be evaluated.
Integrated backscatter as a continuous variable is unlikely to be of
great benefit to practical clinical decision making. A major objective of
a prospective trial would be to establish a “cutoff” value above which
prophylactic anticoagulation could be recommended. This binary
outcome is unlikely to be more informative than a qualitative estimate,
such as the presence or absence of moderate/severe SEC. Although
quantitative assessment of SEC by integrated backscatter provides an
interesting new research tool, we propose that qualitative grading may
be adequate for the majority of clinical studies.
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